Scilex Pharmaceuticals Inc. announced that Express Scripts has added ZTlido® 1.8% to its commercial national formularies representing nearly 30 million lives. ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia, also referred to as post-shingles pain. ZTLIDO is a topical system product that uses an advanced adhesion technology, providing more efficient lidocaine delivery than Lidoderm® over a full 12 hours. Poor adhesion is the most common complaint of lidocaine patches, and ZTLIDO has proven adhesion superiority over Lidoderm®. PHN is the most common complication of shingles, a condition caused by the herpes zoster virus. PHN affects an estimated 1 million people in the United States each year.